Brooks Laboratories Limited
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment
What Brooks files
- Others51
- Important16
- Board Meeting9
- Updates5
- Credit Ratings2
- Results2
Brooks Laboratories will hold its Annual General Meeting. Shareholders should note the book closure period and the availability of e-voting options leading up to the meeting.
Brooks Labs signed an MoU with Steriscience Specialties & BSL. It reduces Brooks' BSL stake to 32.67% for ₹106.33 Cr cash. The agreement protects Brooks' remaining investment value and defines future capital/dilution terms, plus releases its guarantees.
Brooks Laboratories approved selling 51,220 shares in Brooks Steriscience Limited for ₹106.33 Cr. This partial monetization will fund the company's growth strategy and capacity enhancement. It will retain 32.67% ownership.
Brooks Labs (BROOKS) approved selling 51,220 shares in Brooks Steriscience to Steriscience Specialties for ~₹106.33 Cr. This partial divestment reduces BROOKS's stake from 49% to 32.67%. Funds will be deployed for company growth, expansion, and new business opportunities.
Brooks Laboratories' 23rd Annual General Meeting will be held on September 26, 2025. The company announced a book closure period from September 20 to September 26, 2025, for the AGM. This window determines shareholder eligibility for voting. E-voting runs from September 23-25.